Abstract
Despite adequate sample size and high enrollment of patients with confirmed gram-negative sepsis, E5 did not improve short-term survival. Current study rationale and designs should be carefully reviewed before further large-scale studies of patients with sepsis are conducted.
Keywords
MedicinePlaceboInterim analysisSepsisSeptic shockClinical endpointRandomized controlled trialAdverse effectInternal medicineShock (circulatory)Relative riskConfidence interval
Affiliated Institutions
Related Publications
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
Treatment with drotrecogin alfa activated significantly reduces mortality in patients with severe sepsis and may be associated with an increased risk of bleeding.
Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis
Objectives: Corticosteroids may be beneficial in sepsis, but uncertainty remains over their effects in severe influenza. This systematic review updates the current evidence rega...
Publication Info
- Year
- 2000
- Type
- article
- Volume
- 283
- Issue
- 13
- Pages
- 1723-1723
- Citations
- 261
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
261
OpenAlex
Cite This
Derek C. Angus
(2000).
E5 Murine Monoclonal Antiendotoxin Antibody in Gram-Negative Sepsis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>.
JAMA
, 283
(13)
, 1723-1723.
https://doi.org/10.1001/jama.283.13.1723
Identifiers
- DOI
- 10.1001/jama.283.13.1723